(Q37542952)

20 August 2017

1 reference

title

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions (English)

1 reference

20 August 2017

1 reference

A Gualberto

1

1 reference

PubMed ID

19581933

20 August 2017

M Pollak

series ordinal

2

1 reference

PubMed ID

19581933

20 August 2017

language of work or name

English

0 references

publication date

6 July 2009

1 reference

20 August 2017

1 reference

20 August 2017

28

1 reference

20 August 2017

3009-3021

1 reference

20 August 2017

34

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2009.172

20 August 2017

0 references

cites work

Integrated profiling of basal and luminal breast cancers.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Growth patterns and the risk of breast cancer in women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Insulin-like growth factor-I receptor signaling blockade combined with radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The IGF‐1 receptor in cancer biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The type 1 insulin-like growth factor receptor pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Insulin receptor expression by human prostate cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Quantitative mass spectrometry identifies insulin signaling targets in C. elegans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Growth hormone receptor is expressed in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Development of monoclonal antibodies for the treatment of colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The insulin-like growth factor 1 receptor in cancer: old focus, new future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Igf1r as a therapeutic target in a mouse model of basal-like breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Gastrosplenic fistula from Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Epidermal growth factor receptor targeting in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Targeting polo-like kinase: learning too little too late?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Insulin and insulin-like growth factor signalling in neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Targeting insulin and insulin-like growth factor signalling in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Presence of somatomedin receptors on primary human breast and colon carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Insulin-like growth factors and neoplasia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The insulin-like growth factor system and its pleiotropic functions in brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Disrupting insulin-like growth factor signaling as a potential cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The role of the IGF system in cancer growth and metastasis: overview and recent insights

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

IGF-1 receptor inhibitors in clinical trials--early lessons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Targeting insulin-like growth factor pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Gene expression profiles in normal and cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.172

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/ONC.2009.172

1 reference

20 August 2017

1 reference

PubMed ID

19581933